| Title |
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
|
|---|---|
| Published in |
BMC Urology, January 2014
|
| DOI | 10.1186/1471-2490-14-9 |
| Pubmed ID | |
| Authors |
Tobias Engel Ayer Botrel, Otávio Clark, Rodolfo Borges dos Reis, Antônio Carlos Lima Pompeo, Ubirajara Ferreira, Marcus Vinicius Sadi, Francisco Flávio Horta Bretas |
| Abstract |
Prostate cancer is the most common cancer in older men in the United States (USA) and Western Europe. Androgen deprivation (AD) constitutes, in most cases, the first-line of treatment for these cases. The negative impact of CAD in quality of life, secondary to the adverse events of sustained hormone deprivation, plus the costs of this therapy, motivated the intermittent treatment approach. The objective of this study is to to perform a systematic review and meta-analysis of all randomized controlled trials that compared the efficacy and adverse events profile of intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic hormone-sensitive prostate cancer. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 78 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 16% |
| Student > Bachelor | 11 | 14% |
| Researcher | 9 | 11% |
| Student > Ph. D. Student | 8 | 10% |
| Student > Postgraduate | 7 | 9% |
| Other | 17 | 21% |
| Unknown | 15 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 49% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Computer Science | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Other | 11 | 14% |
| Unknown | 18 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2014.
All research outputs
#13,168,771
of 22,741,406 outputs
Outputs from BMC Urology
#306
of 747 outputs
Outputs of similar age
#159,316
of 306,469 outputs
Outputs of similar age from BMC Urology
#7
of 12 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 747 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,469 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.